QRxPharma Ltd. (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.  The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales.  QRxPharma’s lead drug compound, MoxDuo™ IR (Q8003IR), began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

QRxPharma Successfully Completes Comparative Study for Dual-Opioid™ Pain Therapy 
20 April 2009

RedChip Announces CEO Interviews and Company Presentations from Its 2009 San Francisco Conference Now Available Online
8 April 2009

QRxPharma Initiates Second Comparative Study for MoxDuo™ IR Dual-Opioid™ Pain Therapy
19 February 2009

QRxPharma Expands Management Team with the addition of Dr. Jesus Soriano as Executive Vice President
22 January 2009

QRxPharma Initiates Comparative Study for MoxDuoIR™ Dual-Opioid™ Pain Therapy
16 December 2008

QRxPharma and University of Alabama at Birmingham Collaborate on Research Program for Parkinson’s Disease 
29 October 2008

FDA Accepts Streamlined Phase 3 Development Plan for Q8003IR “Dual Opioid” Pain Therapy 
5 August 2008

QRxPharma Begins Trading on the International OTCQX 
1 July 2008

QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy 
22 May 2008

QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 
5 May 2008

Bioshares: The Commercial Context for QRxPharma’s QR8003 
11 April 2008

The Commercial Context for QRxPharma’s QR8003QRxPharma Limited Interim Report for the half-year ended 31 December 2007 
26 February 2008

QRxPharma Initiates Second Phase III Clinical Trial for its ‘Dual Opioid’ Pain Therapy 
13 December 2007

QRxPharma Moving Rapidly with First Patients Enrolled in Phase III Clinical Trial Programme for its “Dual Opioid” Pain Therapy 
--The Australian Investor, November 2007

QRxPharma Doses First Patients in Phase III Clinical Trial Program for its ‘Dual Opioid’ Pain Therapy 
26 November 2007

QRxPharma Annual report 2007 
27 September 2007

QRxPharma On Track as Dual Opioid Phase III Trials Approach Full Clinical Readiness 
15 August 2007

JP Morgan Analyst Report 
4 July 2007

QRxPharma Trials Recipe for Pain Relief 
28 June 2007 - The Australian Financial Review

Australian firm combines with local biotech entrepreneur in U.S. venture
21 June 2007 - Washington Business Journal

QRxPharma Completes $50 Million IPO; Trading Commences on the Australian Securities Exchange 
25 May 2007